Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Larimar Therapeutics ( (LRMR) ) has shared an update.
On October 14, 2025, Larimar Therapeutics announced updated clinical data for nomlabofusp, a potential disease-modifying therapy for Friedreich’s Ataxia. The data showed promising results, with improvements in clinical outcomes and increased frataxin levels in patients. Despite some cases of anaphylaxis, the therapy was generally well tolerated, leading to a modified dosing regimen approved by the FDA. Larimar plans to submit a Biologics License Application in the second quarter of 2026, aiming for accelerated approval.
The most recent analyst rating on (LRMR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.
Spark’s Take on LRMR Stock
According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.
Larimar Therapeutics’ stock score reflects its early-stage biotech status with high R&D costs, no consistent revenue, and reliance on equity financing. Despite positive short-term technical indicators suggesting upward momentum, the lack of profitability and a negative P/E ratio weigh heavily on the stock. Valuation concerns and the absence of earnings call insights further impact the score.
To see Spark’s full report on LRMR stock, click here.
More about Larimar Therapeutics
Larimar Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for rare diseases. Its primary product in development is nomlabofusp (CTI-1601), which is aimed at treating Friedreich’s Ataxia, a rare and progressive disease with significant unmet medical needs.
Average Trading Volume: 2,558,683
Technical Sentiment Signal: Hold
Current Market Cap: $363.8M
Find detailed analytics on LRMR stock on TipRanks’ Stock Analysis page.